<DOC>
	<DOC>NCT02211885</DOC>
	<brief_summary>Study to characterize the pharmacokinetics of 14C-radiolabeled BIRB 796 BS and its metabolites including excretion and mass balance of parent compound and radioactivity; to isolate, identify and quantify major radiolabeled metabolites of BIRB 796 in plasma, urine and feces</brief_summary>
	<brief_title>Excretion Balance of 14c-radiolabeled BIRB 796 BS in Normal Male Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male subjects as determined by results of screening. Health is confirmed by medical history, physical examination, laboratory testing and 12lead electrocardiogram (ECG) Signed written informed consent in accordance with Good Clinical Practice Age ≥ 18 and ≤ 45 years Subjects within 10% of the normal height: weight range defined by the Metropolitan Life Insurance Company Tables Any finding of the medical examination (including blood pressure, pulse rate, and ECG) deviating from normal and of clinical relevance History of clinically significant disease including metabolic, endocrinologic, immunological, hepatic, renal, gastrointestinal, respiratory, cardiovascular, psychiatric or neurological History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Subjects with a history of drug abuse or alcoholism Chronic or relevant acute (within 1 month of screening) infections Subjects who have taken prescription within one month or overthecounter drugs within two weeks of the start of the trial Participation in another trial with an investigational drug (≤ 2 months prior to administration or during trial) Inability to refrain from smoking on trial days Blood donation &gt; 400 mL (within 1 month prior to administration or during the trial) Any laboratory value outside 10% of the reference range of clinical relevance (but not exclusive to) total white cell count ≥ 10 x 10**9/L, any hemoglobin &lt; 12 mg/dl or &gt;15 mg/dl. Protein on urine dipstick Positive urine drug screen, positive HIV or Hepatitis C antibodies History of any familial bleeding disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>